GTC
DYN icon

Ghost Tree Capital’s Dyne Therapeutics DYN Stock Holding History

Ghost Tree Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$3.59M Buy
+100,000
New +$3.98M 1.09% 34

Other funds holding DYN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Ghost Tree Capital's DYN Position: Q3 2024 in Review

Ghost Tree Capital opened a new position in Dyne Therapeutics (DYN) in Q3 2024: 100,000 shares worth $3.59M. The stake represents 1.09% of the portfolio and ranks #34 among its holdings.

200 funds tracked by Wall St. Rank hold DYN as of Q3 2024.

  • Ghost Tree Capital held 100,000 shares of Dyne Therapeutics worth $3.59M as of Q3 2024.
  • Dyne Therapeutics was a new Ghost Tree Capital position in Q3 2024.
  • Dyne Therapeutics made up 1.09% of Ghost Tree Capital's portfolio in Q3 2024, its #34 holding.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.